1.
O’Brien S. Minimal residual disease elimination by consolidation therapy with alemtuzumab. Hematol Meeting Rep [Internet]. 2009 May 28 [cited 2024 Nov. 23];1(2). Available from: https://www.pagepress.org/journals/hmr/article/view/227